Straits Times Index
3,291.14 +18.42 (+0.56%) Nikkei
38,282.50 +730.34 (+1.95%) Hang Seng
16,828.93 +317.24 (+1.92%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,715.28 -401.33 (-0.60%) CMC Crypto 200
1,435.74 +20.98 (+1.48%)
SciSparc Ltd. (SPRC)
After hours:
| Previous close | 1.2200 |
| Open | 1.2400 |
| Bid | 1.1900 x 100 |
| Ask | 1.2600 x 100 |
| Day's range | 1.2004 - 1.2400 |
| 52-week range | 1.1500 - 23.6600 |
| Volume | |
| Avg. volume | 1,351,008 |
| Market cap | 3.326M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -326.4000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSciSparc to Acquire AutoMax
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel. According to the Agreement, the Company will acquire 100% of AutoMax and establi
- GlobeNewswire
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived th
- GlobeNewswire
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the develo
